Phaseline

Companies › MIBIO PTE.

MIBIO PTE.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rhTPO
Recombinant human thrombopoietin (TPO) receptor agonist
THPOPhase 3Thrombocytopenia Associated With Chronic Liver DiseaseOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07911800rhTPOPhase 3Thrombocytopenia Associated With Chronic Liver DiseaseHematologyOct 2028

Targets

THPO (1)

Companies with the same targets

Geropharm Sichuan Clover Biopharmaceuticals Chongqing Peg-Bio Biopharm

Companies built like this

Pharmanutra Vega Therapeutics VarmX Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.